Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWeiwei SuiLQLugui Qiu

Discussion

Loading...

Member takes

Overview

Clinical trial evaluates CART-ASCT-CART2 strategy, showing high complete response rates in TP53 abnormal myeloma patients.

Key Points

  • Complete response achieved in all 14 patients with multiple myeloma after CART-ASCT-CART2 regimen, indicating effective treatment.
  • Cytokine release syndrome occurred in 57.1% of cases following first CAR-T, with recovery observed in all patients.
  • Autologous stem cell transplantation combined with BCMA-targeted therapy utilized a standardized lymphodepletion method.
  • Despite promising outcomes, TP53 mutations suggest a risk of early relapse, demanding innovative interventions.

Cite This Study

Sui et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da9chttps://doi.org/10.1182/blood-2025-4068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia2025 · 2 citations
  2. 2BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  3. 3BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 2 citations
  4. 4CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  5. 5Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma2025